President Donald Trump has nominated Dr. Casey Means, a physician and health tech entrepreneur, as the next U.S. Surgeon General. The announcement, made Wednesday, highlights Means' alignment with Health Secretary Robert F. Kennedy Jr.’s "Make America Healthy Again" initiative.
Dr. Means, 37, co-founded the health technology company Levels, which uses data from continuous glucose monitors to help users understand how their food choices affect metabolic health. She is a strong advocate for using personalized data to drive healthier lifestyles and is widely seen as a rising voice in the preventive health and biohacking movement.
Her brother, Calley Means, was recently appointed as a White House adviser, focusing on food policy reform and addressing corporate influence on national health trends. Together, the Means siblings have been vocal supporters of reshaping American health through nutrition-focused and tech-driven approaches.
Dr. Means will replace Trump’s previous nominee, Dr. Janette Nesheiwat, who the president announced will now serve in a different senior role within the Department of Health and Human Services alongside Secretary Kennedy.
As Surgeon General, Dr. Means would become the nation’s leading spokesperson on public health, responsible for delivering science-based guidance on disease prevention, wellness, and reducing chronic illness. Her nomination is expected to energize health reform advocates who support lifestyle medicine and digital health innovation.
Trump’s pick signals a continued shift toward preventive care and a broader embrace of alternative health strategies that prioritize nutrition, metabolic awareness, and data-driven wellness tools. The nomination must still be confirmed by the Senate.


Iran Plans New Gulf Restricted Zone as Hormuz Tensions Push Oil Higher
Costa Rica President Backs Potential US Ground Operations
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
Ecuador Backs U.S. Sinking of Vessels in Pacific Anti-Drug Operation
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
AfD Eyes Historic Win in Saxony-Anhalt Election
Israel Strikes Southern Lebanon After Hezbollah Drone Attack
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
Brazil Warns EU of Retaliation Over Animal Products Ban
Kyiv Mothers Give Birth Amid Russian Drone Attacks
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Trump Peace Envoys Meet Zelenskiy in Kyiv After Putin Talks
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 



